Dual SEGOVA (DOS - Dual Ovarian Stem cell Therapy) is an absolutely unique, most advanced cutting-edge third level ovarian rejuvenation program, integrating tissue-based regenerative techniques alongside two types of stem cells and bioactive factors to restore ovarian function with the highest level of precision and effectiveness.

​

A recent publication in the renowned  International Journal of Molecular Sciences presents the DOS method, showcasing cutting-edge advancements in treatment technologies.

 

In DOS therapy, we simultaneously utilize two types of autologous stem cells (SC) – mesenchymal and hematopoietic. These cells are extracted from bone marrow (mesenchymal and hematopoietic) and sometimes peripheral blood (predominantly hematopoietic). Their abilities to differentiate, modulate the immune response, and stimulate angiogenesis make them powerful tools in regenerative reproductive medicine.

 

The key principle of DOS is the concurrent application of mesenchymal and hematopoietic stem cells, which synergistically enhance each other's effects. This approach allows for the collection of a significantly larger number of stem cells, with the possibility of cryopreservation for future use, thereby improving the overall outcomes of the therapy.

These two types of stem cells are used in conjunction with biological scaffolds, bioregenerative fibrine derived from the patient's own blood to ensure local retention and enhance the desired effects. Growth factors from PRP are used for in vitro ovarian tissue activation. 

 

Active Principles in Dual SEGOVA Therapy:

 

• hc PRP – Activated autologous highly concentrated platelet growth factors

• BRF – Activated autologous bio-regenerative fibrin

• mSC – Mesenchymal stem cells

• hSC – Hematopoietic stem cells

• IVA – In Vitro Activated ovarian tissue

• Metabolic and Physical Optimization – Patient involvement in metabolic optimization and specialized training

 

Dual SEGOVA (DOS) procedure consist of the following:

 

1. Preparation:

This phase lasts for several days or weeks and includes comprehensive analyses of hormones, immunological status, infections, metabolism, vitamins, microelements, and genetics.

​

2. Execution of the DOS Procedure:

• a single or a two-day stay in the hospital, general anaesthesia

• blood is drawn from the patient to process highly concentrated autologous PRP and BRF (fully automatized closed system)

• creation of the autologous thrombin.

• biopsy of the iliac bone and aspiration of the bone marrow

• separation and processing of mSC  from the bone marrow aspirate concentrate (fully automatized closed system)

• separation and processing of hSC  from the bone marrow aspirate concentrate (fully automatized closed system)

• minimally invasive laparoscopic surgery with tangential ovarian cortex excision.

• application of autologous activated haemostatic BRF instead of classical destructive surgical techniques

• IVA processing and micro-fragmentation of ovarian tissue submerged in mediums with autologous activated hcPRP

• creation of subcortical tunnels for the re-transplantation

• Application of autologous activated brf scaffold in the adequate subcortical tunnels

• application of the micro fragmented IVA ovarian cortical tissue with mSC, hSC and hc PRP into the adequate subcortical spaces

• closure of the tunnels and re-creating the ovarian surface with the activated autologous BRF.

• control of haemostasis

• discharge from the hospital in 1 or 2 days.

 

3. Additional Activities:

• consultations with a nutritionist for metabolic optimization.

• participation in a gonadal HIIT program guided by a physiotherapist.

 

4. Reproductive Follow-up:

• regular ultrasound and laboratory monitoring.

• recommendations or implementation of advanced in vitro fertilization techniques.